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Gene therapy works, as several children
cured of the severe immune disorder
called ‘‘bubble boy disease’’ can attest.
But as currently practiced, the method is
imprecise—sometimes the new DNA
lands in an unsuitable part of the genome,
doing more harm than good. Fortunately,
a recent advance in gene targeting may
soon improve this outlook. This new tech-
nology is based on a class of natural DNA-
binding molecules called zinc-finger pro-
teins (ZFPs) that can be engineered to
precisely target any part of the genome.
When combined with a suitable effector
domain, the ZFP can activate, suppress,
mutate, or repair the selected gene. Al-
though zinc-finger (ZF) technology is still
in development, promising clinical results
are already emerging. ‘‘What we hope to
achieve during the next few years is the
ability to put a gene at any given place in
the genome, and to fix or cut out any spe-
cific disease-causing gene,’’ says Carlos
Barbas, III, Ph.D., of The Scripps Re-
search Institute (TSRI) in La Jolla, Califor-
nia. ‘‘With this technology, we can shape
the genome in ways that would otherwise
be impossible.’’
Naturally occurring ZFPs are transcrip-
tion factors (TFs) that home in on and
bind to specific DNA sequences. Modular
in structure, the molecules grip the DNA
using a number of elongated units, each
made of about 30 amino acids folded
into a compact domain and stabilized by
zinc ion. ‘‘I deduced the existence of this
repeated motif, which I called zinc finger
(ZF), and realized it would be a powerful
method for making general DNA-binding
proteins,’’ says Sir Aaron Klug, a Chemis-
try Nobel Laureate who discovered the
proteins in 1985 in the egg cells of the
Xenopus frog. Since then, researchers
have identified ZFPs in many other spe-
cies, including humans—indeed, more
than 700 human genes code for them.
Klug and his colleagues demonstrated
that each finger independently binds to
a specific sequence of three base pairs
(bp) of DNA that depends on the protein’s
amino acid composition. ‘‘It’s a powerful
and unique system for gene intervention,’’
says Klug.
Barbas, who had earlier studied DNA
targeting using small molecules, became
intrigued by this discovery. In the early
90s, he built ZFs that recognized all DNA
triplets of the form Gnn. His team at
TSRI has since added most of the Cnn,
Tnn, and Ann triplets to their library. The
researchers showed that two or more fin-
gers could be placed in tandem to recog-
nize longer sequences, and the ensemble
could be coupled to various effector do-
mains such as transcription activators or
repressors. In 2000, Barbas targeted on
the first human gene using this technol-
ogy—the erbB2 oncogene implicated in
breast tumors. This was a challenging tar-
get: the 18bp stretch in erbB2 the ZFP
was designed to recognize differed by
only 3 bp from an erbB3 segment. Despite
this potential for confusion, the protein hit
its mark accurately; a similar molecule
that targeted erbB3 was equally precise.
‘‘That told us that we could reach into
the genome and specifically tickle any
given gene,’’ says Barbas.
Meanwhile, Dana Carroll, Ph.D., at the
University of Utah in Salt Lake City, Utah
was looking for a more efficient way to tar-
get genes. The existing method, widely
used even now, was to insert into the nu-
cleus a strand of donor DNA carrying the
replacement gene sandwiched between
sequences identical to those flanking the
original gene, in the hope that the cell’s re-
pair machinery would swap the old DNA
for the new. Unfortunately, such ‘‘homolo-
gous’’ recombination happens only in
about one in a million cells: a high enough
rate for making knockout mice but too low
for manipulating other organisms, includ-
ing rats. One way to increase it is to intro-
duce a double-stranded break in the DNA
on or near the gene. But this is easier said
than done—DNA can be cut with endonu-
cleases, but doing this at the right spot on
the genome is tricky. ‘‘So I looked around
for reagents that could make targetable
double strand breaks,’’ says Carroll.
In 1996, Carroll found what he was look-
ing for. A group at Johns Hopkins Bloom-
berg School of Public Health, Baltimore,
Maryland, led by Srinivasan Chandrase-
garan, Ph.D., had just built the first ZF nu-
clease, combining a ZFP with the cleavage
domain of the Fok1bacterial nuclease and
successfully marrying the specificity of the
one with the DNA-snipping capability of
the other. ‘‘I got really excited about its po-
tential to target recombinogenic double-
strand breaks,’’ says Carroll. However,
the first ZF nuclease Carroll obtained
from Chandrasegaran didn’t hit the ex-
pected target. In solving this puzzle, the
researchers discovered that the Fok1 do-
main has to dimerize before it can act;
cleavage occurs when two matching ZF
half-nucleases bind DNA head-to-head,
effectively assembling the cleavage re-
agent at the target site. Since both mole-
cules have to recognize their targets, the
double binding ensures high specificity.
‘‘This is one of the absolutely fabulous fea-
tures of these reagents,’’ says Carroll. ‘‘It
would have been very difficult to design,
but we got it for free.’’
After showing that ZF nucleases could
make double-stranded breaks and trigger
homologous recombination in Xenopus
egg cells, Carroll turned his attention to
Drosophila. Armed with a set of ZFs from
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knocked out the fruit fly’s y gene. ‘‘It
showed for the first time that we could
hit a real gene at its normal genomic site
in a real organism,’’ says Carroll. Since
then, Carroll and other researchers have
obtained similar results with a number of
other organisms, including the zebrafish,
the roundworm, and the tobacco plant,
as well as with several mammalian cell
types, including human cancer and stem
cells. They have shown that even a tran-
siently expressed nuclease can induce
a permanent and heritable change in the
cell’s genome.
In the 90s, two companies sprang up
around this new technology: UK-based
Gendaq, founded by Klug, and Richmond,
California-based Sangamo Biosciences.
Sangamo, now a publicly traded company
with a market capitalization of about $100
million, acquired Gendaq in 2001. In 2002,
Sangamo researchers demonstrated reg-
ulation of theVEGF-Agene in mice. ‘‘It was
the first successful use of a ZF TF in a hu-
man disease model,’’ says Philip Gregory,
D. Phil., vice president of research at the
company. This compound is now in clini-
cal trials for diabetic neuropathy and Lou
Gehrig’s disease. In 2003, researchers en-
gineered a six-finger protein that inhibited
the checkpoint kinase 2 (CHK2) gene
while leaving all 16,000 other genes in
two cell lines unaffected. ‘‘We demon-
strated the astonishing specificity that’s
possible with these reagents,’’ says Greg-
ory. This year, Sangamo researchers suc-
cessfully made a human T cell line resis-
tant to HIV by knocking out the CCR5
gene with a nuclease. The company ex-
pects to file an investigational new drug
(IND) application this year and to conduct
a phase I trial of this compound.
Precise gene targeting potentially elimi-
nates the risks associated with random
transgene insertion, which is a major con-
cern with conventional gene therapy. But
ZF technology offers other potential bene-
fits as well. Unlike transgenes, engineered
TFs act ‘‘naturally’’ on endogenous genes,
ensuring that all splice isoforms of the tar-
get proteins are produced in the correct
ratio. For instance, tissues given aVEGF-A
transgene or the growth factor itself grow
leaky vessels due to missing isoforms. In
contrast, mice treated with a ZF TF in the
Sangamo VEGF-A study developed nor-
mal blood vessels. ZF therapy is particu-
larly suitable for conditions such as cancer
that are more often related to disregulated
gene expression rather than mutations.
‘‘We can use these proteins to reprogram
a cancer cell to become more epithelial-
looking by reactivating tumor suppressor
pathways,’’ says Pilar Blancafort, Ph.D.,
of the University of North Carolina at
Chapel Hill.
From the practical standpoint, it is eas-
ier to work with a small gene therapy vec-
tor carrying a TF rather than a typically
larger one encoding cDNA. This also
makes targeting multiple genes easier.
‘‘We can hit the cell several times, one
after the other, and whatever epigenetic
change we induce will stay and reinforce
one another,’’ says Marianne Rots,
Ph.D., of the University Medical Center
Groningen in the Netherlands. Correcting
mutations is also simpler with ZF technol-
ogy–instead of a complete replacement
gene, only a small segment with the cor-
rect sequence needs to be provided.
Promising as it sounds, though, ZF
technology has to surmount many chal-
lenges before it is ready for the clinic.
The ZFP’s specificity, its chief attraction,
is often imperfect; even six-finger proteins
sometimes bind incorrectly. This is less of
a concern for TFs, since a wayward mole-
cule will rarely hit a coding region. For nu-
cleases, however, the problem is seri-
ous—an off-target DNA break could kill
the cell. To prevent incorrect binding, re-
searchers such as David Segal, Ph.D., of
the University of California at Davis, have
reengineered the Fok1 dimerization inter-
face. ‘‘We took a nuclease that was toxic
to cells and turned into something that
wasn’t toxic,’’ says Segal.
An engineered ZFP is typically tested
first on ‘‘naked’’ DNA in vitro. To make
it work inside the cell, however, the na-
ture of the chromatin at the gene locus,
how the DNA wraps around the nucleo-
some, and other epigenetic factors have
to be considered. ‘‘All this will have an
impact on how the ZFPs will work, but
people have not looked much into that,’’
says Pernette Verschure, Ph.D., of the
University of Amsterdam in the Nether-
lands. Fortunately, studies indicate that
ZFPs are not greatly impeded by some
epigenetic barriers such as methylated
or condensed chromatin. ‘‘We are able
to reach DNA targets that we thought
were completely inaccessible,’’ says
Blancafort.
Despite its modular structure, assem-
bling a working ZFP is trickier than simply
connecting a bunch of ZFs in tandem. Not
all permutations of ZFs are compatible;
finding ones that work often involves
complex design strategies as well as
considerable trial-and-error. Researchers
unwilling to invest this much effort could
instead purchase custom-made ZF nu-
cleases from Sigma-Aldrich, which
started marketing the compounds under
license from Sangamo this September.
Currently, the price tag is high—about
$25,000 per nuclease kit, according to
Sigma-Aldrich market segment manager
Phil Simmons—but will eventually de-
crease once the reagents become off-
the-shelf commodities. ‘‘Once people
can go online to order their ZFPs, it will
be the technology of choice to modify
the genome,’’ says Barbas.
Chandra Shekhar (chandra@nasw.org) is a science
writer based in Princeton, NJ.1242 Chemistry & Biology 15, December 22, 2008 ª2008 Elsevier Ltd All rights reserved
